Pexidartinib
- Generic Name
- Pexidartinib
- Brand Names
- Turalio
- Drug Type
- Small Molecule
- Chemical Formula
- C20H15ClF3N5
- CAS Number
- 1029044-16-3
- Unique Ingredient Identifier
- 6783M2LV5X
- Background
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial gia...
- Indication
Pexidartinib is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery.
- Associated Conditions
- Symptomatic Tenosynovial Giant Cell Tumor
- Associated Therapies
- -
Merck drug for rare tumour hits phase 3 target
Merck KGaA's pimicotinib, a CSF-1R inhibitor, achieved a 54% objective response rate in a phase 3 trial for tenosynovial giant cell tumour (TGCT), outperforming Daiichi Sankyo's Turalio and potentially Ono's vimseltinib. The drug showed efficacy in reducing joint stiffness and pain, with Merck now planning to register it as the first systemic therapy for TGCT in China.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath